U.S. Markets open in 5 hrs 41 mins

Soligenix, Inc. (SNGX)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
2.09-0.09 (-4.13%)
At close: 3:59PM EDT
People also watch
CBLIAPHBIDXGHTGMFCSC

Soligenix, Inc.

29 Emmons Drive
Suite C-10
Princeton, NJ 08540
United States
609-538-8200
http://www.soligenix.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees19

Key Executives

NameTitlePayExercisedAge
Dr. Christopher J. Schaber Ph.D.Chairman, Chief Exec. Officer and Pres598.27kN/A50
Ms. Karen R. KrumeichChief Financial Officer, Sr. VP and Corp. Sec.152.07kN/A63
Dr. Richard C. Straube M.D., MSc.Chief Medical Officer and Sr. VP413.06kN/A65
Dr. Oreola Donini Ph.D.Chief Scientific Officer and Sr. VPN/AN/A45
Mr. Adam T. RumageVP of Project Management & Regulatory AffairsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates through two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn’s disease and acute radiation enteritis. This segment also offers SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer. The Vaccines/BioDefense segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase IB clinical trial for the treatment of vaccine against ricin toxin poisoning; VeloThrax, an anthrax vaccine candidate; OrbeShield, a GI acute radiation syndrome (GI ARS) therapeutic candidate, which is in pre-clinical stage to treat therapeutics against GI ARS; and SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of melioidosis. Its vaccines are supported by its ThermoVax, a heat stabilization technology. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey.

Corporate Governance

Soligenix, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.